GSK Investigational Site

Dnipropetrovsk 49102

0 studies enrolling now · 31 studies all time

What they study most

Acute Coronary Syndrome, Asthma, Carcinoma, Hepatocellular, Crohn's Disease, Diabetes Mellitus, Diabetes Mellitus, Type 2, Lung Cancer, Non-Small Cell, Melanoma, Pulmonary Disease, Chronic Obstructive, Purpura, Thrombocytopaenic, Idiopathic

Studies at this site

• MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects — Completed
• A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma — Completed
• Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old — Completed
• SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma. — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study — Completed
• Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics — Completed
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease — Completed
• Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma — Completed
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Asthma Exacerbation Study — Completed
• An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. — Completed
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma — Completed
• Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive — Completed
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component — Completed
• Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD) — Completed
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed
• RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag — Completed
• LENS - Long-term Eltrombopag Observational Study — Completed